The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Open accessAbstract
RationaleThis dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, and behavior.ObjectivesThis double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.MethodsParticipants were 18 adults (17 hallucinogen-naïve). Five 8-h sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (nine participants each). Placebo was scheduled quasi-randomly. During sessions, volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.ResultsPsilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.ConclusionsUnder supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood, and behavior. Implications for therapeutic trials are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High MEQ-30 scores have also been found to predict changes in personality-trait openness (MacLean et al., 2012) and positive changes in attitudes, mood, and behavior (Griffiths et al., 2011).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Griffiths et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it has been repeatedly found that psychedelic-induced mystical-type experiences and ego dissolution, the latter a phenomenon characterized by the reduction in self-referential awareness, disruption self-world boundaries, and increased feelings of unity with one’s surroundings (55), correlates with long-term (positive) outcomes (23, 52–54, 56–58).”
From Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to the active placebo group, both groups which received a high dose of psilocybin reported significantly higher enhancements in mood, well-being and life satisfaction, as assessed by the Persisting Effects Questionnaire (87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“phase I and II studies suggest a dose-dependent effect on the quality of the psychedelic experience [54, 76]”
The cited source says what the claim attributes to it.
In the citing paper
“5 mg of psilocybin was shown to induce subjective changes significantly greater than those of an inert placebo; [76]”
The cited source says what the claim attributes to it.
In the citing paper
“with high mystical experience scores associated with 30 mg/70 kg of psilocybin [76]”
The cited source says what the claim attributes to it.
In the citing paper
“Undergoing a mystical-type experience during the acute effects of a psychedelic has been associated with healthy volunteers reporting an improvement in their wellbeing [51, 52], and reductions in depression symptoms in participants with life-threatening cancer [19, 20].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Mindfulness meditation and mindfulness-based interventions can augment positive affect in healthy and clinical populations acutely and long-term (10, 88) and a similar mood-enhancing potential has been demonstrated for psychedelics such as psilocybin (29, 38, 60, 83, 87).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
The cited source says what the claim attributes to it.
In the citing paper
“Controlled studies where subjects achieved mystical experiences under the effects of psilocybin showed personal long-term benefits (Griffiths et al., 2008; Griffiths et al., 2011).”
From Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach (2018) · cites this paper as Griffiths et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Importantly, previous studies utilising psychedelic-administration outside of a mindfulness-enhancing context have failed to show such positive trait changes (83, 87, 133), with the exception of trait openness (74, 134).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [87]
Experimental — accuracy not yet measuredIn the citing paper
“and a dose-response study in healthy volunteers suggested that optimum psilocybin dosing for eliciting a well-tolerated yet transcendent experience may be between 0·29 mg/kg and 0·43 mg/kg [32].”
From Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. (2020) · cites this paper as [32]
In the citing paper
“Self-reported increases in interpersonal closeness and positive/altruistic social effects were reported 1, 2, 6, and 14 months after one and two administrations of psilocybin (89–92).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 23×
“The questionnaire included three additional questions (see Griffiths et al. 2006 for more specific wording): (1) How personally meaningful was the experience?”
BackgroundMethodResultInfluentialSelf-citationThe Psychology of Religion: An Empirical Approach
Donahue, M. J., Hood, R. W., Spilka, B., Hunsberger, B. E., & Gorsuch, R. L. (1998) · Journal for the Scientific Study of Religion · doi:10.2307/1388044 · Cited by 1,339
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationMartin, W. R., Sloan, J. W., SAPIRA, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 945
The Psychology of Religion: An Empirical Approach
Hall, C. M., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Journal for the Scientific Study of Religion · doi:10.2307/1386305 · Cited by 943
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Psychology of Religion: An Empirical Approach
Hunsberger, B. E., Spilka, B., Hood, R. W., & Gorsuch, R. L. (1986) · Review of Religious Research · doi:10.2307/3511875 · Cited by 626
Research works printed but not linked: 5
- Metzner R (2004) Teonanacatl: sacred mushroom of visions. Four Tree, El Verano
- Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Rev 5:3–39
- Pahnke W (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. in Religion and Society
- Stolaroff MJ (1997) The secret chief revealed. Multidisciplinary Association for Psychedelic Studies, Sarasota
- VandeCreek L (1999) The death transcendence scale. In: Hill PC, Hood RW Jr (eds) Measures of religiosity. Religious Education Press, Birmingham, pp 442–445
Cited by
Sorted by citations
Items 901–979 of 979
Véliz‐García, Ó., & Domic‐Siede, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00454
The Promise and the Paradox: Exploring Eating Disorder Discourse in Psychedelic Reddit CommunitiesPreprint
Shannon, F., & Dykeman, C. (2025) · Research Square · doi:10.21203/rs.3.rs-8188928/v1
Changing minds: bioethical dimensions of psychedelic-assisted psychotherapy
Jacobs, E. (2025) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qq0qxrok6
Psychedelic biomedicalization: mainstreaming a scientific revolution
Neitzke‐Spruill, L. (2023) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/6yb4-rd10
Murphy, R. J., Sumner, R. L., Evans, W. J., Menkes, D., Lambrecht, I., Ponton, R., Sundram, F., Hoeh, N. R., Ram, S., Reynolds, L., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14478492
Ramos, L. I. N. P. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/erq0-ba03
Hurwitz, E. S. (2024) · eScholarship (California Digital Library)
Crawford, B. (2024) · UCL Discovery (University College London)
Meðferðir við vímuefnavanda : gætu hugvíkkandi efni verið ákjósanlegur valkostur í meðferðum?
Víðisdóttir, H. S., & Þórsdóttir, G. B. (2021) · Skemman
Phenomenal consciousness without a self: Ego dissolution and its philosophical bearings
Caserta, F. (2023) · DiVA at Umeå University (Umeå University)
Bailey, F. (2023) · UCL Discovery (University College London)
Johnstad, P. G. (2016) · NORA - Norwegian Open Research Archives
Psychoterapeutické účinky psilocybinu
Bromová, D. (2024) · Digital library - University of Pardubice (University of Pardubice)
Lindecrantz, L., & Villman, N. (2023) · University Library of Skövde (University of Skövde)
PSILOCYBIN MOT BEROENDE_Effekter vid alkoholberoende och tobaksberoende
Lindqvist, M. (2023) · DiVA at Umeå University (Umeå University)
Oder, A. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Valente, N., Acosta, L. E., Piazza, N., col, J. D., Puili Alippi, T., & Lavagnino, N. (2024) · RIDAA-UNQ Repositorio Institucional de Acceso Abierto de la Universidad Nacional de Quilmes
Kremer, M. (2024) · MOnAMi (Hochschule Mittweida Hochschulbibliothek)
Understanding the Microdosing of Psychotropic Drugs in Mentally Distressed Young Adults
Žagar, S. (2025) · Repository of the University of Ljubljana (University of Ljubljana)
Gonçalves, J. D. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Bisson, M. D. (2023) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/18057
Set, Setting, and Surrender: The Influences on Psychedelic Experiences and Their Impact on Wellbeing
Hayat, Y. (2023) · UCL Discovery (University College London)
Life Reviews in Near-Death Experiences and in Theosophy
Tassell-Matamua, N., Savinainen, A., & Greyson, B. (2024) · The Journal of near-death studies · doi:10.17514/jnds-2024-42-2-p85-102
Μπαλαπανίδης-Παρίσης, Χ.-Ν. Δ., & Μπαλαπανίδης-Παρίσης, Χ.-Ν. Δ. (2024) · University of Thessaly Institutional Repository (University of Thessaly)
Hurevich, M. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Pallavicini, C., Llobenes, L., Cavanna, F., de la Fuente, L. A., Müller, S., Costa, M. I., Gumiy, N., Bruno, N. M., D’Amelio, T. A., Basran, J. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.17.694940
Cassidy, E. K., Davis, A. K., & Rao, S. (2025) · Psychedelics · doi:10.1016/j.psyche.2025.100007
Diehl, V. J., Calder, A. E., & Hasler, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251397306
Rabinovitch, B. S., Silverman, N., Ji, D., Shizgal, D., Lewis, E. C., & Carlen, P. L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150142
Baseline Mood and “Relational Triad” Predict Acute Qualities of Psychedelic Experience
Lipson, J., Kettner, H., Carhart-Harris, R. L., & Miller, L. (2026) · Behavioral Sciences · doi:10.3390/bs16020310
Santé mentale et psychédéliques : révolution ou promesse utopique ?
Duguey, A. L., Fauvel, B., & Bioy, A. (2025) · Perspectives Psy · doi:10.1051/ppsy/2025055
Cohorst, A., & Kajonius, P. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424199
Zong, Z. (. (2023) · Tuwhera (Auckland University of Technology)
Henningfield, J. E., Barrett, F. S., Evans, S. M., Garcia‐Romeu, A., Garrett, B. E., Hienz, R. D., Lukas, S. E., Nayak, S. M., Strain, E. C., Weerts, E. M., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251398801
Aguirre, G. M. V., Sempértegui, O., & Guerra, A. (2024) · GIGAPP Estudios Working Papers
Gallardo, L. M. (2026) · Preprints.org · doi:10.20944/preprints202604.0415.v1
Stocker, K., Hartmann, M., Barrett, F. S., Richards, W. A., Sepeda, N. D., Ley, L., Becker, A. M., Holze, F., & Liechti, M. E. (2026) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.70073
Self-citationWilde, A. (2026) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Pavăl, D. (2026) · SpringerBriefs in religious studies · doi:10.1007/978-3-032-20214-7_1
Pavăl, D. (2026) · SpringerBriefs in religious studies · doi:10.1007/978-3-032-20214-7_5
The Phenomenology of Psychedelic Experiences
Pavăl, D. (2026) · SpringerBriefs in religious studies · doi:10.1007/978-3-032-20214-7_2
Nayak, S. M., Sepeda, N. D., Dick, M. N., Tiwari, P., Zahid, Z., Sayalı, C., Weiss, B., Yaden, D. B., Garcia‐Romeu, A., Barnett, B. S., et al. (2026) · medRxiv · doi:10.64898/2026.04.28.26351625
Exploring new avenues: Psychedelic‐assisted therapy for young people
Vamvakopoulou, I. A., Nicholls, D., Nutt, D. J., & Simplicio, M. D. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70579
Can Childhood be Used as a Model to Understand the Effects of Psychedelics?
Hurwitz, E. S., Dean, J. G., & Walker, C. M. (2026) · Topics in Cognitive Science · doi:10.1111/tops.70058
Oleksowicz, M. (2026) · Synthese Library/Synthese library · doi:10.1007/978-3-032-19252-3_9
Virtue ethics as a means of mitigating perverse effects in academia
Skowron, B., & Morawski, R. Z. (2026) · Humanities and Social Sciences Communications · doi:10.1057/s41599-026-07697-9
The Possibility of Simulating Psychedelic Experiences in Virtual Reality Using Psyrreal
Schihalejev, S. (2026) · DSpace repository (University of Tartu)
Reynante, B. M., & Buchanan, J. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00523
Clark, T. A. (2025) · The Therapeutic Conversation · doi:10.66330/100520252
Calder, A. E., Diehl, V. J., Hinney, B., & Hasler, G. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101127
Psychedelic therapy at the end of life: unexplored alternative to assisted suicide in the UK
Zinchenko, R. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10729
van Mulukom, V. (2026) · Neuroscience of Consciousness · doi:10.1093/nc/niag033
Longitudinal neural and psychological changes following psilocybin under compassion imagery priming
Pallavicini, C., Llobenes, L., Cavanna, F., de la Fuente, L. A., Muller, S. L., Costa, M., Gumiy, N., Bruno, N. M., D’Amelio, T. A., Basran, J. K., et al. (2026) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2026.1874178
On the functional significance of quantum effects at subneuronal scales
Roeloffs, J., & Tuszyński, J. A. (2026) · Biosystems · doi:10.1016/j.biosystems.2026.105905
Vidal, J., Andreu, C. I., Fuentes-Ferrada, R., & Cebolla, A. (2026) · Mindfulness · doi:10.1007/s12671-026-02955-y
Mason, N. L., Mallaroni, P., Kuypers, K. P. C., de la Torre, R., Reckweg, J. T., Preller, K. H., & Ramaekers, J. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.04.742704
Milczanowski, A. (2026) · Research Square · doi:10.21203/rs.3.rs-10705756/v1
Broman, M. J., Acharya, J. N., Ahmed, K., Armstrong, S. B., & Davis, A. K. (2026) · Current Addiction Reports · doi:10.1007/s40429-026-00774-8
Psychedelic, Entheogenic, and Transpersonal Experiences
Winkelman, M. (2026) · Wiley eBooks · doi:10.1002/9781394215683.ch24
Age moderates the relationship between psychedelic use and mental health in naturalistic settings
Gregorio, G. D., Sophia, B., Manmohan, H., Nixon, W. C., Pogaku, A., Zhou, J., Sanderson, D. J., Lengieza, M. L., & Bocchio, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-68283-2
Barrett, F. S., Wolinsky, D., Daily, Z., Ciancio, J., Arthur, K., & Vandrey, R. G. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07138-0
Passie, T., & van Elk, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478606
Why taking the trip out of psychedelic medicine is a mistake
Heller, J., & Hendlin, Y. H. (2026) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2026.105487
De la révélation à l’intégration : enjeux socio-épistémiques de l’expérience psychédélique
Vallée, M. (2026) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/36133
Bendz, J. (2026) · Lund University Publications Student Papers (Lund University)
Ehrenkranz, R. C., Sepeda, N. D., Goldy, S. P., Weiss, B., Tiwari, P., Azimi, A., & Yaden, D. B. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473405
The role of expectation in ketamine treatment for teatment-resistant depression
Pajer, M. (2026) · Repository of the University of Ljubljana (University of Ljubljana)
Signor, A., Comai, S., Pasut, G., Folli, F., Gentilucci, M., Gharavi, N., Raitsin, S., Nguyen, T. V., Pappagallo, M., Mattarei, A., et al. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70839
Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis
Maekawa, R. M., Guerra, L. T. L., Villanova, B., de Paula, C. C., Vicentini, A. B., Rodrigues, L. S., Reis, J. A. S., Rossi, G. N., Bouso, J. C., Hallak, J. E. C., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002264
Iudica, M. A. (2026) · Repositorio Institucional UCA (Pontificia Universidad Católica Argentina)
Effets, motifs, impacts et contexte de l’usage non-médical de substances psychédéliques
Leclerc, C.-A. (2025) · Le dépôt institutionnel (Université du Québec à Trois-Rivières)
Toimijuus ja kasvinäkökulmahypoteesi klassisten psykedeelien antropologisessa tutkimuksessa
Kuusisto, T. (2022) · UEF eRepo (University of Eastern Finland)
Dames, S. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00552
Floris, G., Jefferson, S. J., Rondeau, J. A., Yu, A. L., Menniti, F. S., Kwan, A. C., Aquino, J. P. D., Krystal, J. H., Pittenger, C., & Kaye, A. P. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02569-x
do Nascimento, R. M. M., da Silva, E. L. F., Falci, V. D., Ayres, A. C. F., Oliveira, J. P. A., Rodrigues, T. P. G., de Souza, L., & da Silva, R. D. F. (2026) · Revista Foco · doi:10.54751/revistafoco.v19n11-038
Davis, A. K., Sepeda, N. D., Armstrong, S. B., Douglas, A., Lewis, B. R., Xin, Y., Romanella, T., & Ellis, S. E. (2026) · Chronic Stress · doi:10.1177/24705470261503829
Metadata
- Authors
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- Psychopharmacology
- Published
- 2011-06-15
- Volume
- 218
- Issue
- 4
- Pages
- 649-665
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC3308357
- OpenAlex
- W2001101493
- Semantic Scholar
- b6a466d47ff14211f273622e5d0b584d06253237
- Cited by
- 932
- References
- 38
- Citations by year
- 2026: 59 · 2025: 97 · 2024: 115 · 2023: 110 · 2022: 107 · 2021: 94 · 2020: 64 · 2019: 65 · 2018: 48 · 2017: 51 · 2016: 40 · 2015: 18 · 2014: 23 · 2013: 18 · 2012: 14
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (R01DA003889, R01DA03889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, dose-response relationship, fear and anxiety, long-term psychological effects, psychedelic therapy
- MeSH terms
- Adult, Affect, Attitude, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Time Factors, Cross-Over Studies, Spirituality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
